EE311 Cost-Effectiveness Analysis of Ruxolitinib vs Best Available Therapy for the Treatment of Myelofibrosis in the United States

Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.556
https://www.valueinhealthjournal.com/article/S1098-3015(22)00757-4/fulltext
Title : EE311 Cost-Effectiveness Analysis of Ruxolitinib vs Best Available Therapy for the Treatment of Myelofibrosis in the United States
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00757-4&doi=10.1016/j.jval.2022.04.556
First page :
Section Title :
Open access? : No
Section Order : 10495
Categories :
Tags :
Regions :
ViH Article Tags :